Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with
migraine-like features in people with persistent post-traumatic headache (PTH) attributed to
mild traumatic brain injury (mTBI).